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Abstract. Individuals with newly diagnosed tuberculosis (TB) were screened for diabetes (DM) with fasting plasma
glucose (FPG) in Pakistan. A signiﬁcant decrease in FPG was observed when TB was treated. Of those with newly
diagnosed DM, 46% and 62% no longer had hyperglycemia after 3 and 6 months, respectively. Individuals with known
DM also showed a signiﬁcant decrease in fasting plasma levels when treated for TB, but after 3 months none had
normoglycemia, and after 6 months 9.2% were normoglycemic. Thus, TB-related DM may abate when the stress ter-
minates, as is the case in gestational DM. However, because stress hyperglycemia may be associated with subsequent
risk of developing DM, follow-up is recommended.
INTRODUCTION
Diabetes (DM) increases the risk of developing tuberculosis
(TB) and subsequent treatment failure.1,2 Pakistan is experi-
encing adramatic increase inDMand reported aprevalenceof
6.9% in 2015. In Pakistan, DMhealth care is often left to family
physicians with limited training and knowledge about di-
agnosis, monitoring, and prevention of complications.3 The
collision of the two diseases is, therefore, of great concern in
regionswhere TB is endemic. TBmay, as is the casewith other
infections and conditions such as pregnancy, induce stress-
related transient hyperglycemia, leading to overdiagnosis of
DM. Stress hyperglycemia related to TB may be the result of
insulin resistance caused by a complex interaction between
catecholamines, cortisol, growth hormones, and cytokines.4,5
Stress-related insulin resistance results in hyperglycemia by
two pathways: 1) hepatic overproduction of glucose, mainly
through an inability to suppress gluconeogenesis and 2) pe-
ripheral defects in insulin-mediated glucose uptake. Stress
hyperglycemia itself enhances the inﬂammatory response
leading to further increase in blood glucose levels; a self-
reinforcing cycle that may worsen outcomes and increase
mortality.6 Despite the fast growing literature on DM enhanc-
ing the risk of TB, there are only few studies, mostly small, on
the course of hyperglycemia in TB.7–10 The present study
aimed to observe in more detail 1) changes in fasting plasma
glucose (FPG) levels over time, 2) the extent to which these
values are related to glycemic status when initiating TB
treatment, and 3) the optimal time to screen and rescreen for
DM in individuals with TB.
MATERIALS AND METHODS
The present study was part of a larger screening study de-
scribed elsewhere.11 Individuals with newly diagnosed smear
positive TB ³ 25 years of age were invited to participate in the
study between May 2014 and September 2015. Data were
collected at Gulab Devi Chest Hospital, Lahore, Pakistan.
Pregnant women and individuals with concomitant infections
or type 1 diabetes mellitus were excluded. TB was diag-
nosed according to the national guidelines for control of TB
in Pakistan, and directly observed treatment, short course
was offered.12 All suspected TB cases delivered two spu-
tumsamples formicroscopyof Ziehl–Neelsen stained smears.
The results of sputum smear microscopy repeated at 2 and
5 months were also recorded. FPG was measured at enrol-
ment in 462 individuals with newly diagnosed TB. Of these,
198 individuals were followed-up after 3 months of TB treat-
ment, whereas 264 individuals had their FPG repeated after
6 months of anti-TB treatment. Having more than one initial
and one follow-up FPGwas refused bymost participants and,
therefore, not enforced. FPG was measured between 8 and
10 AMafter at least 8 hours of fastingona capillary sample using
Hemocue 201 RT (A¨ngelholm, Sweden). DM was classiﬁed as
screen-detectedDM (SDM) or knownDM (KDM), according to
history. SDM diagnosis was based on the World Health Or-
ganization (WHO) criteria, where values of FPG ³ 7.0 mmol/L
are diagnostic for DM.13 Individuals with SDM who remained
hyperglycemic after 3 months of TB treatment were informed
about the risks of adverse TB outcomes and were recom-
mended to have their blood glucose levels retested after
completion of the treatment, whereas those with hypergly-
cemia after 6 months were advised to visit a DM clinic. Indi-
viduals with KDM and hyperglycemia were recommended to
consult the doctor responsible for their DM treatment. All
participants gave written consent, and ethics approval was
obtained from the National Bioethics Committee, Pakistan
(No.4-87/14/NBC-139/RDC4936). The median difference in
FPGover timewasassessedusingWilcoxon signed-rank test,
and differences in proportions of individuals who had hyper-
glycemia were assessed using the McNemar’s test. The as-
sociation between hyperglycemia and treatment outcomes
was evaluated by χ2 test.
RESULTS
Baseline characteristics for the two DM groups are de-
scribed in Table 1; SDM individuals were younger and had
signiﬁcantly lower body mass index, waist–hip ratio, and
blood pressure. The participants did differ signiﬁcantly from
the cohort from whom they were enrolled regarding anthro-
pometric or biochemical parameters (results not shown).
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At enrolment, 42.2% (N = 195) of the participantswith TBwere
diagnosed with SDM, and 26.0% (N = 120) had KDM. FPG
decreased over time for both groups (SDMandKDM); in SDM,
the median decrease (interquartile range [IQR] 25;75) was
1.2mmol/L (0.5;3.1)and2.1mmol/L (1.2;3.0)after3and6months,
respectively. For individuals with KDM, the median decrease in
FPG was 1.5 mmol/L (1.0;3.6) and 1.7 mmol/L (0.6;3.5) after 3
and 6months, respectively. The decrease in FPG over time was
signiﬁcant for both groups at 3months (P< 0.001) and 6months
follow-up (P < 0.001) (Figure 1). For individuals with SDM, 46%
reverted to normoglycemia after 3 months of anti-TB treatment,
whereas 62% became normoglycemic after 6 months. For TB
patients with KDM, 88.2%were hyperglycemic at baseline and,
none of these became normoglycemic after 3months of anti-TB
treatment (P = 0.31), whereas 9.2% of those who were hyper-
glycemicatbaselinebecamenormoglycemicafter 6months (P=
0.34). Most of the participants with KDM (80%) were receiving
DM treatment at the time of TB diagnosis, but we did not have
information on whether DM treatment was adjusted during TB
treatment.
A positive sputum smear at 2 or 5 months after anti-TB
treatment start was not associatedwith hyperglycemia (FPG ³
7.0 mmol/L) at baseline (P = 0.30). Of the 462 participants, six
(1.3%) died. There was no association between hyperglyce-
mia at baseline and mortality (P = 0.44) nor between hyper-
glycemia at 6 months and death (P = 0.66).
DISCUSSION AND CONCLUSION
Individuals with TB and DM, whether SDM or KDM, expe-
rienced a highly signiﬁcant decrease in FPG over time after
anti-TB treatment. Hyperglycemia is associated with poor TB
outcome, and even though a notable number of individuals
with SDM had transient hyperglycemia, 38% remained with
hyperglycemia after 6 months of anti-TB treatment, under-
lining the importance of screening for DM in individuals with
TB.7 Previous studies have found that stress hyperglycemia
may unveil underlying DM in up to 60% of hospital-admitted
patients.14,15 Most individuals with KDM remained hypergly-
cemic at follow-up, despite receiving DM treatment, but it is
important to note that the decrease in FPG was signiﬁcant.
Therefore, optimization of DM treatment in individuals with TB
is important. Although we did not obtain detailed information
on whether DM treatment or diet was adjusted during TB
treatment, the persistent hyperglycemia suggests that DM
treatmentwas not intensiﬁed. Another limitation of our study is
that FPGmeasurement was not repeated at 3 and 6months in
all participants. IndividualswithSDMwere informedabout and
were aware of the possibility of stress-related hyperglycemia.
Less than 10%of those with SDM hadmarked hyperglycemia
(FPG ³ 14.0 mmol/L); all those with marked hyperglycemia
were advised to have their FPG repeated within a couple of
days by a private doctor. Because of limited resources, we
assumed that most participants did not invest in a visit to a
private doctor or initiate DM treatment during the course of TB
treatment, but the lack of information on treatment of DM
during TB follow-up was an important limitation of our study.
In conclusion, the number of participants reverting to normo-
glycemia increased as anti-TB treatment progressed. Even
though theWHOrecommendsscreening forDMat the start of TB
treatment, a deﬁnite diagnosis of newly diagnosedDMcannot be
ascertained before anti-TB treatment has been completed.16
Transient-elevated plasma glucosemay predict the development
of DM. Screening for DM after recovery from stress has been
shown to be cost effective and may decrease the risk of associ-
atedcomplications.17Becausetransienthyperglycemia inTBmay
also indicate subsequent increased risk for manifest DM, we still
recommend following individuals whose FPG normalized during
TB treatment; however, atpresent there isnotenoughevidence to
suggest a length of follow-up time, or whether individuals with
SDM should be recommended diet and lifestyle changes.
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TABLE 1
Baseline biological characteristics for tuberculosis patients with screen-detected diabetes (SDM) and known diabetes (KDM); presented as mean
(95% CI)
Variable SDM (N = 195) KDM (N = 120) P value*
Male (n (%) 129 (65.8) 73 (60.8) 0.10
Age (years) 43 (41:45) 47 (46:49) < 0.001
Weight (kg) 50.3 (48.8:52.0) 57.0 (54.8:59.0) < 0.001
Height (cm) 163 (161:164) 162 (160:163) 0.46
Body mass index (kg/m2) 19.0 (18.4:19.6) 21.7 (21.0:22.5) < 0.001
Waist (cm) 65.7 (63.8:67.6) 73.2 (71.3:75.5) < 0.001
Hip (cm) 79.2 (78.0:80.4) 84.0 (82.5:85.5) < 0.001
Waist–Hip ratio 0.82 (0.80:0.84) 0.87 (0.85:0.89) < 0.001
Hemoglobin (g/dL) 11.7 (11.4:11.9) 11.8 (11.4:12.1) 0.56
Systolic blood pressure[BP] (mm of Hg) 103 (100:105) 116 (113:119) < 0.001
Diastolic BP (mm of Hg) 67 (66:68) 75 (73:77) < 0.001
Pulse (beats/minutes) 107 (104:109) 107 (104:109) 0.95
*Between-group comparison of TB patients with SDM and KDM was performed using a t-test and χ2 test for continuous and categorical variables, respectively.
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